ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ARVN Arvinas Inc

41.33
0.00 (0.00%)
Pre Market
Last Updated: 04:00:00
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 17.15
Ask Price 65.93
News -
Day High

Low
13.57

52 Week Range

High
53.08

Day Low
Company Name Stock Ticker Symbol Market Type
Arvinas Inc ARVN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 41.33 04:00:00
Open Price Low Price High Price Close Price Prev Close
41.33
Trades Volume Avg Volume 52 Week Range
0 0 - 13.57 - 53.08
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 41.33 USD

Arvinas (ARVN) Options Flow Summary

Overall Flow

Bullish

Net Premium

343k

Calls / Puts

100.00%

Buys / Sells

100.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

Arvinas Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
2.81B 68.08M - 78.5M -367.3M -5.39 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Arvinas News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ARVN Message Board. Create One! See More Posts on ARVN Message Board See More Message Board Posts

Historical ARVN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week44.7544.8540.3441.75419,497-3.42-7.64%
1 Month47.4651.5140.3444.72805,670-6.13-12.92%
3 Months41.2453.0835.41544.55769,1990.090.22%
6 Months20.3353.0813.5734.61766,13121.00103.30%
1 Year26.4153.0813.5731.45593,29414.9256.49%
3 Years59.72108.46513.5748.40496,501-18.39-30.79%
5 Years15.51108.46513.5747.06481,73825.82166.47%

Arvinas Description

Arvinas Inc is a United States-based private biopharmaceutical company focused on developing first-in-class protein degradation therapeutics for cancers and other difficult-to-treat diseases. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. Its pipeline candidates include metastatic castration-resistant prostate cancer, metastatic ER-breast cancer, additional oncology indications, tauopathies, and other neurodegenerative diseases. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.

Your Recent History

Delayed Upgrade Clock